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
Home / What’s new? / Patents
Patents
Patent
Novel sulfonamidocarboxamide compounds as NLRP3 inhibitors and their preparation
Number
WO 2019/008025 A1
Year
2020
Customer
Inflamazone
Patent
NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
Number
WO 2020/089456 A1WO 2020/089459 A1
Year
2020
Customer
AiCuris
Patent
NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[4,3-C]PYRIDINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
Number
WO 2020/089452 A1
Year
2020
Customer
AiCuris
Patent
NOVEL UREA 6,7-DIHYDRO-4H-THIAZOLO[5,4-C]PYRIDINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
Number
WO 2020/089460 A1
Year
2020
Customer
AiCuris
Patent
paration of substituted sulfonyl triazoles and related heteroaryl compounds as as NLRP3 inhibitors usefulin treatment and prevention of diseases
Number
WO 2019/211463 A1
Year
2020
Customer
Inflamazone
Patent
Preparation of novel sulfonamide carboxamide compounds as NLRP3 inhibitors
Number
WO 2019/034696 A1WO 2019/034697 A1WO 2019/034686 A1
Year
2020
Customer
Inflamazone
Patent
Preparation of sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
Number
WO 2019/008029 A1
Year
2020
Customer
Inflamazone
Patent
Sulfonamide derivates as NLRP3 inhibitors and their preparation
Number
WO 2019/166633 A1
Year
2020
Customer
Inflamazone
Patent
1,2,4-triazolederivatives as tankyrase inhibitors
Number
WO 2019/243822 A1
Year
2019
Customer
Oslo University
Patent
Method for the preparation of a 2,4,5-trisubstituted 1,2,4-triazole
Number
WO2019/197239 A1
Year
2019
Customer
Bayer Pharma
